Sun, F. et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide proven cardiovascular benefits in type 2 diabetes mellitus (T2DM) and heart failure, but their effects in patients with peripheral artery disease (PAD) remain unclear.
meta-analysis of 6 RCTs in participants with T2D found that tirzepatide reduced systolic blood pressure (SBP) in a dose-dependent manner, by 3.6, 4.4 and 6.1 mmHg for 5, 10 and 15 mg, respectively, compared with placebo (Lv et al. 2024).
Such details provide a deeper understanding and appreciation for Glp-1 Effects On Blood Pressure In T2D.
GLP-1 analogues and combination therapies represent innovative approaches to managing T2DM and mitigating cardiovascular risk. The robust evidence from clinical trials underscores their potential to improve patient outcomes by addressing both metabolic and cardiovascular aspects of the disease.
CVOTs have shown that GLP-1 receptor agonists reduce MACE in patients with T2D compared to placebo. In addition, they have positive impact on several cardiovascular risk factors such as obesity by promoting weight loss, blood pressure and blood lipid levels.
Such details provide a deeper understanding and appreciation for Glp-1 Effects On Blood Pressure In T2D.
This systematic review aims to assess the long-term cardiovascular effects of GLP-1 RAs in adults with T2D compared to placebo, standard care, or other glucose-lowering medications.
